These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Serum calprotectin: a new potential biomarker for thyroid papillary carcinoma. Tabur S; Korkmaz H; Özkaya M; Elboğa U; Tarakçıoglu M; Aksoy N; Akarsu E Tumour Biol; 2015 Sep; 36(10):7549-56. PubMed ID: 25916207 [TBL] [Abstract][Full Text] [Related]
3. Investigation of the role of 8-OHdG and oxidative stress in papillary thyroid carcinoma. Tabur S; Aksoy ŞN; Korkmaz H; Ozkaya M; Aksoy N; Akarsu E Tumour Biol; 2015 Apr; 36(4):2667-74. PubMed ID: 25434875 [TBL] [Abstract][Full Text] [Related]
4. [Expression of microRNA-221 and IL-17 in papillary thyroid carcinoma and correlation with clinicopathologic features]. Jiang XL; Zhang H; Chen YL; Peng L Zhonghua Bing Li Xue Za Zhi; 2017 Mar; 46(3):160-165. PubMed ID: 28297755 [No Abstract] [Full Text] [Related]
5. [Expression and significance of serum E-cadherin in patients with papillary thyroid carcinoma]. Sun L; Wang DM; Zhang WJ; Zhang J; Wu JF Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Jan; 31(2):123-126. PubMed ID: 29871201 [No Abstract] [Full Text] [Related]
6. Nrf2 is commonly activated in papillary thyroid carcinoma, and it controls antioxidant transcriptional responses and viability of cancer cells. Ziros PG; Manolakou SD; Habeos IG; Lilis I; Chartoumpekis DV; Koika V; Soares P; Kyriazopoulou VE; Scopa CD; Papachristou DJ; Sykiotis GP J Clin Endocrinol Metab; 2013 Aug; 98(8):E1422-7. PubMed ID: 23766517 [TBL] [Abstract][Full Text] [Related]
7. Total oxidant/antioxidant status in sera of patients with thyroid cancers. Wang D; Feng JF; Zeng P; Yang YH; Luo J; Yang YW Endocr Relat Cancer; 2011 Dec; 18(6):773-82. PubMed ID: 22002574 [TBL] [Abstract][Full Text] [Related]
8. Different Expression of Erythrocyte Sedimentation Rate and C-reactive Protein in Papillary Thyroid Carcinoma and Nodular Goiter. Hou X; Jiang L; Chen C; Zhu X; Ge M Clin Lab; 2015; 61(7):793-9. PubMed ID: 26299079 [TBL] [Abstract][Full Text] [Related]
9. Redox Status and Antioxidative Cofactor Metals Influence Clinical and Pathological Characteristics of Papillary Thyroid Carcinoma and Colloid Goiter. Rovcanin B; Stojsavljevic A; Kekic D; Gopcevic K; Manojlovic D; Jovanovic M; Knezevic S; Zivaljevic V; Diklic A; Paunovic I Biol Trace Elem Res; 2020 Oct; 197(2):349-359. PubMed ID: 31811573 [TBL] [Abstract][Full Text] [Related]
10. The correlation of the total antioxidant status (TAS), total oxidant status (TOS) and paraoxonase activity (PON1) with smoking. Aslan R; Kutlu R; Civi S; Tasyurek E Clin Biochem; 2014 Apr; 47(6):393-7. PubMed ID: 24440837 [TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical levels of cyclo-oxygenase-2, matrix metalloproteinase-9 and vascular endothelial growth factor in papillary thyroid carcinoma and their clinicopathological correlations. Meng XY; Zhang Q; Li Q; Lin S; Li J J Int Med Res; 2014 Jun; 42(3):619-27. PubMed ID: 24670538 [TBL] [Abstract][Full Text] [Related]
12. RET/PTC Rearrangements Are Associated with Elevated Postoperative TSH Levels and Multifocal Lesions in Papillary Thyroid Cancer without Concomitant Thyroid Benign Disease. Su X; He C; Ma J; Tang T; Zhang X; Ye Z; Long Y; Shao Q; Shao J; Yang A PLoS One; 2016; 11(11):e0165596. PubMed ID: 27802347 [TBL] [Abstract][Full Text] [Related]
13. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the clinical characteristics of PTC. Hu J; Li C; Liu C; Zhao S; Wang Y; Fu Z Cancer Biomark; 2017; 18(1):87-94. PubMed ID: 28085013 [TBL] [Abstract][Full Text] [Related]
14. Lipid peroxidation and antioxidants status in human malignant and non-malignant thyroid tumours. Stanley JA; Neelamohan R; Suthagar E; Vengatesh G; Jayakumar J; Chandrasekaran M; Banu SK; Aruldhas MM Hum Exp Toxicol; 2016 Jun; 35(6):585-97. PubMed ID: 26270564 [TBL] [Abstract][Full Text] [Related]
15. MicroRNA-222 and microRNA-146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer. Lee JC; Zhao JT; Clifton-Bligh RJ; Gill A; Gundara JS; Ip JC; Glover A; Sywak MS; Delbridge LW; Robinson BG; Sidhu SB Cancer; 2013 Dec; 119(24):4358-65. PubMed ID: 24301304 [TBL] [Abstract][Full Text] [Related]
16. [The expression and significance of trefoil factor 3 and SDF-1/CXCR4 biological axis in papillary thyroid carcinoma]. Xue G; Huang J; Zhang H; Zhang W; Wu J; Shang X Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2014 Jan; 28(2):108-12. PubMed ID: 24738314 [TBL] [Abstract][Full Text] [Related]
17. Postoperative recurrence of papillary thyroid carcinoma with lymph node metastasis. Liu FH; Kuo SF; Hsueh C; Chao TC; Lin JD J Surg Oncol; 2015 Aug; 112(2):149-54. PubMed ID: 26175314 [TBL] [Abstract][Full Text] [Related]
18. Thyroglobulin antibody levels do not predict disease status in papillary thyroid cancer. Smooke-Praw S; Ro K; Levin O; Ituarte PH; Harari A; Yeh MW Clin Endocrinol (Oxf); 2014 Aug; 81(2):271-5. PubMed ID: 24494778 [TBL] [Abstract][Full Text] [Related]
19. LDOC1 inhibits proliferation and promotes apoptosis by repressing NF-κB activation in papillary thyroid carcinoma. Zhao S; Wang Q; Li Z; Ma X; Wu L; Ji H; Qin G J Exp Clin Cancer Res; 2015 Dec; 34():146. PubMed ID: 26637328 [TBL] [Abstract][Full Text] [Related]
20. Diagnostic significance of elevated expression of HBME-1 in papillary thyroid carcinoma. Chen YJ; Zhao RM; Zhao Q; Li BY; Ma QY; Li X; Chen X Tumour Biol; 2016 Jul; 37(7):8715-20. PubMed ID: 26738867 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]